#SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544

More data from PAISLEY, deucravacitinib in SLE Small but significant benefit w/respect to joints, a little disappointing tbh Would like to see this for all manifestations ie pericarditis, pleuritis, etc Anyone have an infographic or useful chart? #ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo

• https://x.com/EBRheum/status/1858206970785706213/photo/1
• https://x.com/EBRheum/status/1858206970785706213/photo/1

Low uptake of SGLT2i in Lupus nephritis SGLT2i users had similar adverse event rates as ACEi/ARB users SGLT2i users experienced more weight loss #ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5

• https://x.com/bella_mehta/status/1858207474039292036/photo/1

Study on SLE treatments: Compared adverse events of anifrolumab vs. belimumab Similar risks for mortality, sepsis, herpes zoster, dialysis, MACE, PE/VTE, COVID-19, URI, pneumonia, and mental illness #ACR24 @RheumNow abst#1527

Alright help me out here; this is pretty implausible, right? Why would be pts be 11% more adherent to UPA? What's the bio-plausibility here? UPA 10% better than other JAKs? Could do a network meta analysis; betting this doens't replicate #ACR24 @RheumNow Abstr#1362 https://t.co/vpPq3vu9Wf

• https://x.com/EBRheum/status/1858196904494186816/photo/1
• https://x.com/EBRheum/status/1858196904494186816/photo/1

No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/IOzckJIfYf https://t.co/8S6FnffVLG

TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies #ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR

• https://x.com/EBRheum/status/1858187090082800118/photo/1

Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja

• https://x.com/drdavidliew/status/1858190305398497317/photo/1

Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb

• Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Di…
• https://x.com/RichardPAConway/status/1858183818525753664/photo/1

STAR trial of GC w/d in RA LDA SEMIRA of GC w/d controlled RA on Toci Very slight disease activity increase, but higher flares No symptomatic adrenal insufficiency, but data of abnormal ACTH stim No good evidence of steroid w/d symptoms Beth Wallace @RheumNow #ACR24 https://t.co/j6UPWlVNIu

• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1